RT Journal Article
T1 The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?
A1 Simões, Ana Rita
A1 Fernández Rozadilla, Ceres
A1 Maroñas Amigo, Olalla
A1 Carracedo Álvarez, Ángel
K1 Colorectal cancer
K1 Adverse drug reactions
K1 Pharmacogenomics
K1 Personalised medicine
K1 Toxicity
AB In recent decades, survival rates in colorectal cancer have improved greatly due to pharmacological treatment. However, many patients end up developing adverse drug reactions that can be severe or even life threatening, and that affect their quality of life. These remain a limitation, as they may force dose reduction or treatment discontinuation, diminishing treatment efficacy. From candidate gene approaches to genome-wide analysis, pharmacogenomic knowledge has advanced greatly, yet there is still huge and unexploited potential in the use of novel technologies such as next-generation sequencing strategies. This review summarises the road of colorectal cancer pharmacogenomics so far, presents considerations and directions to be taken for further works and discusses the path towards implementation into clinical practice
PB MDPI
YR 2020
FD 2020
LK http://hdl.handle.net/10347/24035
UL http://hdl.handle.net/10347/24035
LA eng
NO Simões, A.R.; Fernández-Rozadilla, C.; Maroñas, O.; Carracedo, Á. The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment? J. Pers. Med. 2020, 10, 237
NO This research was supported by grant FIS PI 16/01057- ISCIII (to Á.C.), ISCIII PFIS grant FI17/00215 (to A.R.S.) and Fundación Olga Torres (to C.F.-R.)
DS Minerva
RD 28 abr 2026